Oragenics Inc (OGEN) Short Interest Down 72.5% in January
Oragenics Inc (NYSEAMERICAN:OGEN) was the target of a large decline in short interest in the month of January. As of January 31st, there was short interest totalling 117,933 shares, a decline of 72.5% from the January 12th total of 428,990 shares. Based on an average daily volume of 357,388 shares, the days-to-cover ratio is presently 0.3 days.
Shares of Oragenics (NYSEAMERICAN OGEN) opened at $2.25 on Monday. The stock has a market capitalization of $114.89, a PE ratio of -1.39 and a beta of 1.05. Oragenics has a 52 week low of $0.60 and a 52 week high of $8.20.
ILLEGAL ACTIVITY NOTICE: “Oragenics Inc (OGEN) Short Interest Down 72.5% in January” was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at https://theolympiareport.com/2018/02/12/oragenics-inc-ogen-short-interest-down-72-5-in-january.html.
Oragenics Company Profile
Oragenics, Inc develops, markets and sells probiotics specifically designed to enhance oral health for humans and pets, under the brand names Evora and ProBiora. The Company is focused on offering antibiotics against infectious disease and on developing treatments for oral mucositis. It is engaged in developing its antibiotic product candidate, MU1140, as well as other homolog antibiotic product candidates; researching AG013 in connection with the treatment of Oral Mucositis; commercializing its ProBiora3 probiotic products, and has other product candidates for out licensing or partnering.
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.